Dr. Kristopher S. Lybarger, D.O.
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 193
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
AZ license 012192 · KS license 0538312 · MO license 2015025644 -
Obstetrics & Gynecology Physician
MI license 5101017678 · PA license OS015980
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Centerpoint Medical Center Independence, MO
- Abrazo Arrowhead Hospital Glendale, AZ
- Research Medical Center Kansas City, MO
- Menorah Medical Center Overland PArk, KS
Medical groups
- Valley Perinatal Services LLC (65 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 193
- Services billed
- 473
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 110 | 59 |
| Established patient office or other outpatient visit, 30-39 minutes | 90 | 66 |
| Established patient office or other outpatient visit, 20-29 minutes | 45 | 37 |
| New patient office or other outpatient visit, 60-74 minutes | 33 | 33 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tramadol Hcl Other prescribers in Kansas City, MO | 84 |
| Gabapentin Other prescribers in Kansas City, MO | 83 |
| Ibuprofen Other prescribers in Kansas City, MO | 55 |
| Letrozole Other prescribers in Kansas City, MO | 41 |
| Megestrol Acetate Other prescribers in Kansas City, MO | 21 |
| Lorazepam Other prescribers in Kansas City, MO | 19 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Kansas City, MO | 18 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Kansas City, MO | 15 |
| Methylprednisolone Other prescribers in Kansas City, MO | 14 |
| Lynparza (olaparib) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 121 payments worth $79,756 in total to this clinician.
| Davol Inc. | $49,047 |
|---|---|
| GlaxoSmithKline, LLC. | $27,525 |
| AstraZeneca Pharmaceuticals LP | $2,269 |
| Merck Sharp & Dohme LLC | $392 |
| AbbVie Inc. | $203 |
| Eisai Inc. | $142 |
| Genmab U.S., Inc. | $122 |
| Verastem, Inc. | $33.05 |
| Honoraria | $32,675 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $24,625 |
| Travel and Lodging | $17,922 |
| Food and Beverage | $2,221 |
| Consulting Fee | $2,220 |
| Education | $93.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Davol Inc. Apr 11, 2025 | Honoraria | $6,750 |
| Davol Inc. Jun 11, 2025 | Honoraria | $6,750 |
| GlaxoSmithKline, LLC. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $5,700 |
| GlaxoSmithKline, LLC. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $5,700 |
| Davol Inc. Jan 31, 2025 | Honoraria | $5,000 |
| GlaxoSmithKline, LLC. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $4,800 |
| Davol Inc. May 16, 2025 | Honoraria | $4,725 |
| Davol Inc. Mar 26, 2025 | Honoraria | $4,050 |
| Davol Inc. May 19, 2025 | Honoraria | $4,050 |
| GlaxoSmithKline, LLC. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $3,800 |
All 65 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $5,700 |
| GlaxoSmithKline, LLC. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $5,700 |
| GlaxoSmithKline, LLC. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $3,800 |
| GlaxoSmithKline, LLC. Nov 17, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Denver, CO · in-kind | $782 |
| GlaxoSmithKline, LLC. Nov 17, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Denver, CO · in-kind | $339 |
| GlaxoSmithKline, LLC. Nov 13, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Loveland, CO · in-kind | $941 |
| GlaxoSmithKline, LLC. Nov 13, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Loveland, CO · in-kind | $288 |
| GlaxoSmithKline, LLC. Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $475 |
| GlaxoSmithKline, LLC. Oct 6, 2025 | Compensation for services other than consulting (speaking, faculty) ZEJULA · ONCOLOGY | $950 |
| Davol Inc. Oct 6, 2025 | Honoraria | $900 |
| Davol Inc. Sep 2, 2025 | Honoraria | $450 |
| GlaxoSmithKline, LLC. Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $3,200 |
| Davol Inc. Jun 11, 2025 | Honoraria | $6,750 |
| Davol Inc. May 19, 2025 | Honoraria | $4,050 |
| Davol Inc. May 19, 2025 | Travel and Lodging travel to ALBUQUERQUE, NM · in-kind | $259 |
| Davol Inc. May 19, 2025 | Travel and Lodging travel to ALBUQUERQUE, NM · in-kind | $224 |
| Davol Inc. May 16, 2025 | Honoraria | $4,725 |
| Davol Inc. May 12, 2025 | Travel and Lodging ARISTA · Surgery · travel to Savannah, GA · in-kind | $1,066 |
| Davol Inc. May 12, 2025 | Travel and Lodging ARISTA · Surgery · travel to Savannah, GA · in-kind | $249 |
| Davol Inc. May 8, 2025 | Travel and Lodging ARISTA · Surgery · travel to Warwick, RI · in-kind | $173 |
| Davol Inc. May 7, 2025 | Travel and Lodging ARISTA · Surgery · travel to Warwick, RI · in-kind | $349 |
| Davol Inc. May 5, 2025 | Travel and Lodging ARISTA · Surgery · travel to Newport, KY · in-kind | $126 |
| Davol Inc. May 4, 2025 | Travel and Lodging ARISTA · Surgery · travel to Savannah, GA · in-kind | $35.15 |
| Davol Inc. May 2, 2025 | Travel and Lodging ARISTA · Surgery · travel to Savannah, GA · in-kind | $1,434 |
| Davol Inc. May 2, 2025 | Travel and Lodging ARISTA · Surgery · travel to Albuquerque, NM · in-kind | $174 |
| Davol Inc. May 2, 2025 | Travel and Lodging ARISTA · Surgery · travel to Albuquerque, NM · in-kind | $155 |
| Davol Inc. May 1, 2025 | Travel and Lodging ARISTA · Surgery · travel to Phoenix, AZ · in-kind | $179 |
| Davol Inc. Apr 30, 2025 | Travel and Lodging ARISTA · Surgery · travel to Phoenix, AZ · in-kind | $195 |
| Davol Inc. Apr 16, 2025 | Travel and Lodging ARISTA · Surgery · travel to Phoenix, AZ · in-kind | $35.15 |
| Davol Inc. Apr 15, 2025 | Travel and Lodging ARISTA · Surgery · travel to Phoenix, AZ · in-kind | $1,714 |
| Davol Inc. Apr 11, 2025 | Honoraria | $6,750 |
| Davol Inc. Apr 11, 2025 | Travel and Lodging ARISTA · Surgery · travel to Albuquerque, NM · in-kind | $35.15 |
| Davol Inc. Apr 10, 2025 | Travel and Lodging ARISTA · Surgery · travel to Albuquerque, NM · in-kind | $814 |
| Davol Inc. Apr 2, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $410 |
| Davol Inc. Apr 2, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $256 |
| Davol Inc. Apr 1, 2025 | Travel and Lodging ARISTA · Surgery · travel to Fort Meyers, FL · in-kind | $282 |
| Merck Sharp & Dohme LLC Apr 1, 2025 | Education KEYTRUDA · ONCOLOGY · in-kind | $25.70 |
| Davol Inc. Mar 31, 2025 | Travel and Lodging ARISTA · Surgery · travel to Fort Meyers, FL · in-kind | $262 |
| Davol Inc. Mar 31, 2025 | Travel and Lodging ARISTA · Surgery · travel to Little Rock, AR · in-kind | $140 |
| Davol Inc. Mar 28, 2025 | Travel and Lodging ARISTA · Surgery · travel to Little Rock, AR · in-kind | $158 |
| Davol Inc. Mar 27, 2025 | Travel and Lodging ARISTA · Surgery · travel to Fort Myers, FL · in-kind | $304 |
| Davol Inc. Mar 26, 2025 | Honoraria | $4,050 |
| Davol Inc. Mar 26, 2025 | Travel and Lodging ARISTA · Surgery · travel to Little Rock, AR · in-kind | $245 |
| Davol Inc. Mar 23, 2025 | Travel and Lodging ARISTA · Surgery · travel to Little Rock, AR · in-kind | $35.15 |
| Davol Inc. Mar 21, 2025 | Travel and Lodging ARISTA · Surgery · travel to Little Rock, AR · in-kind | $1,347 |
| Eisai Inc. Mar 21, 2025 | Education Lenvima · Oncology | $68.00 |
| Davol Inc. Mar 12, 2025 | Travel and Lodging ARISTA · Surgery · travel to DALLAS, TX · in-kind | $172 |
| Davol Inc. Mar 10, 2025 | Travel and Lodging ARISTA · Surgery · travel to DALLAS, TX · in-kind | $197 |
| Davol Inc. Mar 9, 2025 | Travel and Lodging ARISTA · Surgery · travel to KANSAS CITY, MO · in-kind | $29.30 |
| Davol Inc. Feb 25, 2025 | Travel and Lodging ARISTA · Surgery · travel to San Diego, CA · in-kind | $35.15 |
| Davol Inc. Feb 24, 2025 | Travel and Lodging ARISTA · Surgery · travel to San Diego, CA · in-kind | $660 |
| Davol Inc. Jan 31, 2025 | Honoraria | $5,000 |
| Davol Inc. Jan 22, 2025 | Travel and Lodging travel to FORT WORTH, TX · in-kind | $472 |
| Davol Inc. Jan 22, 2025 | Travel and Lodging travel to METAIRIE, LA · in-kind | $420 |
| Davol Inc. Jan 22, 2025 | Travel and Lodging travel to SAN ANTONIO, TX · in-kind | $417 |
| Davol Inc. Jan 22, 2025 | Travel and Lodging travel to REDONDO BEACH, CA · in-kind | $388 |
| Davol Inc. Jan 22, 2025 | Travel and Lodging travel to AUSTIN, TX · in-kind | $358 |
| Davol Inc. Jan 22, 2025 | Travel and Lodging travel to METAIRIE, LA · in-kind | $336 |
| Davol Inc. Jan 22, 2025 | Travel and Lodging travel to JACKSON, MS · in-kind | $266 |
| Davol Inc. Jan 22, 2025 | Travel and Lodging travel to AUSTIN, TX · in-kind | $253 |
| Davol Inc. Jan 22, 2025 | Travel and Lodging travel to FORT WORTH, TX · in-kind | $207 |
| Davol Inc. Jan 22, 2025 | Travel and Lodging travel to REDONDO BEACH, CA · in-kind | $195 |
| AstraZeneca Pharmaceuticals LP Jan 14, 2025 | Consulting Fee | $2,220 |
| Davol Inc. Jan 13, 2025 | Travel and Lodging travel to CHERRY CREEK, CO · in-kind | $508 |
| GlaxoSmithKline, LLC. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $4,800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $100,294 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Karyopharm Therapeutics Inc. - A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Genmab U.S., Inc. - A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Karyopharm Therapeutics Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.